GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » EV-to-FCF

Nuvation Bio (Nuvation Bio) EV-to-FCF

: 0.00 (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nuvation Bio's Enterprise Value is $0.00 Mil. Nuvation Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-68.07 Mil. Therefore, Nuvation Bio's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Nuvation Bio's EV-to-FCF or its related term are showing as below:

NUVB.WS' s EV-to-FCF Range Over the Past 10 Years
Min: -7.18   Med: 0   Max: 5.12
Current: -0.83

During the past 4 years, the highest EV-to-FCF of Nuvation Bio was 5.12. The lowest was -7.18. And the median was 0.00.

NUVB.WS's EV-to-FCF is ranked worse than
100% of 384 companies
in the Biotechnology industry
Industry Median: 4.38 vs NUVB.WS: -0.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Nuvation Bio's stock price is $0.2875. Nuvation Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Nuvation Bio's PE Ratio for today is N/A.


Nuvation Bio EV-to-FCF Historical Data

The historical data trend for Nuvation Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - 2.46 4.06

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 3.07 2.87 4.64 4.06

Competitive Comparison

For the Biotechnology subindustry, Nuvation Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's EV-to-FCF falls into.



Nuvation Bio EV-to-FCF Calculation

Nuvation Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-68.068
=0.00

Nuvation Bio's current Enterprise Value is $0.00 Mil.
Nuvation Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvation Bio  (NYSE:NUVB.WS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nuvation Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.2875/0.000
=N/A

Nuvation Bio's share price for today is $0.2875.
Nuvation Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nuvation Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Traded in Other Exchanges
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).